Skip to main content
NewslettersWatchlist

Cardiol Therapeutics(CRDL-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.8200
Day High1.8200
Open:1.8200
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Newsfile
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
Newsfile
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
AllPennyStocks.com
Orphan Drug Designation Sends Shares of this Dual-Listed Life Science Therapy Company Soaring
Newsfile
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Newsfile
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
Newsfile
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
Newsfile
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot
Newsfile
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
Newsfile
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Newsfile
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
TheNewswire.com
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
Newsfile
Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference
Newsfile
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
Newsfile
Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
Newsfile
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
Newsfile
Cardiol Therapeutics Reports Results of 2023 Annual General Meeting
ACCESSWIRE
Sidoti's Micro-Cap Virtual May Conference
Newsfile
Cardiol Therapeutics Announces Year-End 2022 Update on Operations
Newsfile
Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure
Newsfile
Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx(TM) for the Treatment of Recurrent Pericarditis
ACCESSWIRE
60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago
PR Newswire
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
PR Newswire
Air Pollution is a Global Heart and Lung Health Concern
PR Newswire
The Healthcare Companies Fighting the World's Biggest Killers
AccessWire
Market Movers. Today’s Top Stock Picks For New & Trending Opportunities
Globe NewsWire
Proactive headlines including Kodiak Copper, Milestone Scientific, HempFusion Wellness and Major Precious Metals
Globe NewsWire
Proactive news headlines featuring The Valens Company, Alpine 4 Technologies, Cloud DX and Metalla Royalty & Streaming
Globe NewsWire
Proactive news headlines including Genprex, INDVR Brands, QC Copper and Gold and Hillcrest EnergyTechnologies
Globe NewsWire
Proactive news headlines including Vuzix Corporation, American Battery Metals, BioSig Technologies and Canntab Therapeutics
Globe NewsWire
Proactive news headlines including Alternus Energy Group, Vuzix Corporation, Bragg Gaming, Safe-T Group Ltd, HempFusion Wellness and Renforth Resources
Globe NewsWire
Proactive news headlines including Energy Fuels, Tartisan Nickel Corp, Medexus Pharmaceuticals and Falcon Gold

Profile

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.